A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy

Trial Profile

A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2018

At a glance

  • Drugs Cabozantinib (Primary) ; Everolimus
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms METEOR
  • Sponsors Exelixis
  • Most Recent Events

    • 02 May 2018 Status changed from active, no longer recruiting to completed, as reported in an media release.
    • 24 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2019.
    • 26 Mar 2018 Results assessing overall survival and updated safety after follow-up published in the British Journal of Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top